吃奶呻吟打开双腿做受动态图 -亚洲色偷偷色噜噜狠狠99网-日韩精品极品视频在线观看免费-来一水AV@lysav

掃碼關(guān)注公眾號(hào)           掃碼咨詢技術(shù)支持           掃碼咨詢技術(shù)服務(wù)
  
客服熱線:400-901-9800  客服QQ:4009019800  技術(shù)答疑  技術(shù)支持  質(zhì)量反饋  人才招聘  關(guān)于我們  聯(lián)系我們
国产偷窥熟女精品视频大全,乳尖乱颤娇喘连连A片在线观看,亚洲成av人片一区二区密柚
首頁(yè) > 新聞動(dòng)態(tài) > 正文
【4月文獻(xiàn)戰(zhàn)報(bào)】Bioss抗體新增高分文獻(xiàn)精彩呈現(xiàn)
發(fā)表者:北京博奧森生物      發(fā)表時(shí)間:2023-6-21

      截止目前,引用Bioss產(chǎn)品發(fā)表的文獻(xiàn)共24858篇,總影響因子116841.414分,發(fā)表在Nature, Science, Cell以及Immunity等期刊的文獻(xiàn)共58篇,合作單位覆蓋了清華、北大、復(fù)旦、華盛頓大學(xué)、麻省理工學(xué)院、東京大學(xué)以及紐約大學(xué)等國(guó)際知名研究機(jī)構(gòu)上百所。

      我們每月收集引用Bioss產(chǎn)品發(fā)表的文獻(xiàn)。若您在當(dāng)月已發(fā)表SCI文章,但未被我公司收集,請(qǐng)致電Bioss,我們將贈(zèng)予現(xiàn)金鼓勵(lì),金額標(biāo)準(zhǔn)請(qǐng)參考“發(fā)文章 領(lǐng)獎(jiǎng)金”活動(dòng)頁(yè)面。

      近期收錄2023年4月引用Bioss產(chǎn)品發(fā)表的文獻(xiàn)共288篇(圖一,綠色柱),文章影響因子(IF) 總和高達(dá)2009.871,其中,10分以上文獻(xiàn)47篇(圖二)。


圖一


圖二


      本文主要分享引用Bioss產(chǎn)品發(fā)表文章至Nature Nanotechnology, Immunity, Cancer Cell等期刊的5篇 IF>15 的文獻(xiàn)摘要,讓我們一起欣賞吧。


Cell Discovery [IF=38.079]


文獻(xiàn)引用抗體:bsm-41516M

Mouse Anti- SARS-CoV-2 (2019-nCoV) Spike RBD mAb | WB

作者單位:北京大學(xué)未來(lái)技術(shù)學(xué)院生物醫(yī)學(xué)工程系

摘要:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has elicited a worldwide pandemic since late 2019. There has been ~675 million confirmed coronavirus disease 2019 (COVID-19) cases, leading to more than 6.8 million deaths as of March 1, 2023. Five SARS-CoV-2 variants of concern (VOCs) were tracked as they emerged and were subsequently characterized. However, it is still difficult to predict the next dominant variant due to the rapid evolution of its spike (S) glycoprotein, which affects the binding activity between cellular receptor angiotensin-converting enzyme 2 (ACE2) and blocks the presenting epitope from humoral monoclonal antibody (mAb) recognition. Here, we established a robust mammalian cell-surface-display platform to study the interactions of S-ACE2 and S-mAb on a large scale. A lentivirus library of S variants was generated via in silico chip synthesis followed by site-directed saturation mutagenesis, after which the enriched candidates were acquired through single-cell fluorescence sorting and analyzed by third-generation DNA sequencing technologies. The mutational landscape provides a blueprint for understanding the key residues of the S protein binding affinity to ACE2 and mAb evasion. It was found that S205F, Y453F, Q493A, Q493M, Q498H, Q498Y, N501F, and N501T showed a 3–12-fold increase in infectivity, of which Y453F, Q493A, and Q498Y exhibited at least a 10-fold resistance to mAbs REGN10933, LY-CoV555, and REGN10987, respectively. These methods for mammalian cells may assist in the precise control of SARS-CoV-2 in the future.


JOURNAL OF HEPATOLOGY [IF=30.083]



文獻(xiàn)引用抗體:bs-1278R

Anti-8-OHdG (DNA/RNA Damage) pAb | IHC

作者單位:美國(guó)明尼蘇達(dá)州羅切斯特市梅奧診所生物化學(xué)和分子生物學(xué)部

摘要:Background & Aims

The prevalence of non-alcoholic steatohepatitis (NASH)-driven hepatocellular carcinoma (HCC) is rising rapidly, yet its underlying mechanisms remain unclear. Herein, we aim to determine the role of hypoxia-inducible lipid droplet associated protein (HILPDA)/hypoxia-inducible gene 2 (HIG2), a selective inhibitor of intracellular lipolysis, in NASH-driven HCC.

Methods

The clinical significance of HILPDA was assessed in human NASH-driven HCC specimens by immunohistochemistry and transcriptomics analyses. The oncogenic effect of HILPDA was assessed in human HCC cells and in 3D epithelial spheroids upon exposure to free fatty acids and either normoxia or hypoxia. Lipidomics profiling of wild-type and HILPDA knockout HCC cells was assessed via shotgun and targeted approaches. Wild-type (Hilpdafl/fl) and hepatocyte-specific Hilpda knockout (HilpdaΔHep) mice were fed a western diet and high sugar in drinking water while receiving carbon tetrachloride to induce NASH-driven HCC.

Results

In patients with NASH-driven HCC, upregulated HILPDA expression is strongly associated with poor survival....


ADVANCED FUNCTIONAL MATERIALS [IF=19.924]



文獻(xiàn)引用抗體:bs-0287R

Anti-His tag pAb | WB

作者單位:中國(guó)藥科大學(xué)生命科學(xué)與技術(shù)學(xué)院江蘇省生物藥物可提取性重點(diǎn)實(shí)驗(yàn)室和天然藥物國(guó)家重點(diǎn)實(shí)驗(yàn)室

摘要:The efficient delivery of biologics into cells provide unique opportunities to modulate intracellular targets not druggable by conventional small molecules. The supercharged polypeptide (SCP) has become a novel intracellular delivery system due to their special advantages, including enhanced delivery efficiency and serum tolerance. However, owing to their cationic charge and non-specificity characteristics, the in vivo application of SCP is limited. Here, an activatable SCP (ASCP) with a pH-sensitive charge shielding sequence (CSS), a protease cleavage site, and SCP are engineered. This system shows the potential to reduce the non-specific binding and effectively deliver various cargo (peptide, protein, small molecule, and siRNA) into the cytosol not only in vitro but also in vivo. Furthermore, an ASCP fusion protein is designed to co-delivery of peptide (KLA)/siRNA (IKBKE) with different tumorigenesis pathways to triple negative breast cancer (TNBC) for optimal therapeutic outcomes. It is believed that ASCP delivery system will facilitate the development of bioactive molecules for use against intracellular targets. This simple yet versatile delivery system can also pave the way for the co-delivery of multiple therapeutic cargos to address the emerging needs of combination cancer therapy.


NUCLEIC ACIDS RESEARCH [IF=19.16]



文獻(xiàn)引用抗體bs-10966R

Anti-Actin pAb | WB

作者單位:中國(guó)廣東廣州中山大學(xué)附屬第一醫(yī)院兒科

摘要:CST (CTC1-STN1-TEN1) is a telomere associated complex that binds ssDNA and is required for multiple steps in telomere replication, including termination of G-strand extension by telomerase and synthesis of the complementary C-strand. CST contains seven OB-folds which appear to mediate CST function by modulating CST binding to ssDNA and the ability of CST to recruit or engage partner proteins. However, the mechanism whereby CST achieves its various functions remains unclear. To address the mechanism, we generated a series of CTC1 mutants and studied their effect on CST binding to ssDNA and their ability to rescue CST function in CTC1?/? cells. We identified the OB-B domain as a key determinant of telomerase termination but not C-strand synthesis. CTC1-ΔB expression rescued C-strand fill-in, prevented telomeric DNA damage signaling and growth arrest. However, it caused progressive telomere elongation and the accumulation of telomerase at telomeres, indicating an inability to limit telomerase action. The CTC1-ΔB mutation greatly reduced CST-TPP1 interaction but only modestly affected ssDNA binding. OB-B point mutations also weakened TPP1 association, with the deficiency in TPP1 interaction tracking with an inability to limit telomerase action. Overall, our results indicate that CTC1-TPP1 interaction plays a key role in telomerase termination.


ACS Nano [IF=18.027]



文獻(xiàn)引用抗體:bs-0295G-HRP
Goat Anti-Rabbit IgG H&L / HRP | WB

作者單位:北京理工大學(xué)生命科學(xué)學(xué)院

摘要:The intrinsic features and functions of platelets and mesenchymal stem cells (MSCs) indicate their great potential in the treatment of intracerebral hemorrhage (ICH). However, neither of them can completely overcome ICH because of the stealth process and the complex pathology of ICH. Here, we fabricate hybrid cells for versatile and highly efficient ICH therapy by fusing MSCs with platelets and loading with lysophosphatidic acid-modified PbS quantum dots (LPA-QDs). The obtained LPA-QDs@FCs (FCs = fusion cells) not only inherit the capabilities of both platelets and MSCs but also exhibit clearly enhanced proliferation activated by LPA. After systemic administration, many proliferating LPA-QDs@FCs rapidly accumulate in ICH areas for responding to the vascular damage and inflammation and then efficiently prevent both the primary and secondary injuries of ICH but with no obvious side effects. Moreover, the treatment process can be tracked by near-infrared II fluorescence imaging with highly spatiotemporal resolution, providing a promising solution for ICH therapy.

點(diǎn)擊這里查看往期單月Bioss抗體產(chǎn)品文獻(xiàn)引用列表



版權(quán)所有 2004-2026 www.xucheq.com 北京博奧森生物技術(shù)有限公司
通過(guò)國(guó)際質(zhì)量管理體系ISO 9001:2015 GB/T 19001-2016    證書編號(hào): 00124Q34771R2M/1100
通過(guò)國(guó)際醫(yī)療器械-質(zhì)量管理體系ISO 13485:2016 GB/T 42061-2022    證書編號(hào): CQC24QY10047R0M/1100
京ICP備05066980號(hào)-1         京公網(wǎng)安備110107000727號(hào)
黑人巨大精品欧美一区二区免费 | 久久精品女人天堂AV免费观看 | 国产人妻人伦精品| 精品人妻无码区二区三区| 精品国产精品国产偷麻豆| 国产肉体XXXX裸体137大胆| 日本少妇被爽到高潮无码| 国产人与ZOXXXX另类| 色窝窝无码一区二区三区| 精品人体无码一区二区三区| 久久天天躁狠狠躁夜夜AV| 少妇特黄A一区二区三区| 女人18毛片a级毛片免费视频| 日日碰狠狠添天天爽超碰97久久 | 特级做A爰片毛片免费69| 妓院一钑片免看黄大片| 少妇高潮毛片免费看| 日韩精品人妻中文字幕有码| 45分钟做受片免费观看| 免费男人下部进女人下部视频| 扒开腿狂躁女人爽出白浆 | 亚洲AV片不卡无码久久| 锕锕锕锕锕锕锕锕好疼好痛 | 亚洲av高清一区二区三区| 色-情-伦-理一区二区三区| 精品久久久久久久免费人妻| 久久人妻熟女一区二区| 亚洲AV毛片一区二区三区| 国产毛片久久久久久国产毛片| 午夜亚洲AV永久无码精品| 无码JK粉嫩小泬在线观看欧美| 女人与公拘交酡ZOZO| 性生交大片免费看| 久久婷婷色综合一区二区| 国产精品VA在线观看无码不卡| 实拍各种胸走光见奶头| 大肥波BBWWHBBWW| 99久久久无码国产精品不卡| XX性欧美肥妇精品久久久久久| 欧美无人区码SUV| 亚洲午夜无码毛片AV久久小说|